Whole body vibration in cystic fibrosis--a pilot study.
BACKGROUND
In cystic fibrosis (CF), bone mass deficits as well as a lack of muscle mass and force have been described. The bone mass deficits are thought to be at least in part secondary to the reduced muscle mass. Whole body vibration has recently been suggested as an effective technique to increase muscle force and power. The aim of this pilot study was to evaluate the compliance and safety of a side-alternating, whole body vibration platform in patients with CF and to assess its effects on muscle force, muscle power, bone mass and lung function.


METHODS
Eleven adult CF patients participated in a six-months home-based training programme on a whole body vibration platform. Muscle force and power were assessed with three standard manoeuvres on a ground reaction force plate at regular intervals. Bone densitometry was performed at the spine, the radius and the tibia using quantitative computerized tomography.


RESULTS
Regular cardiovascular monitoring did not show any critical drop in oxygen saturation or blood pressure. Lung function remained relatively constant with a median FEV1 change [% of norm] of -3.1% (range -7-20). Trabecular density at the spine and parameters of bone density and geometry at the radius and tibia did not show consistent changes. A median decrease of -0.3% (-31.0-17.9) for muscle force and a median increase of 4.7% (-16.4-74.5) for muscle power and 6.6% (-0.9-48.3) for velocity was noted in the two-leg jump. In the one-leg jump, a median increase of 6.7% (-8.5-24.3) for muscle force was measured.


CONCLUSIONS
Whole body vibration was well tolerated in the majority of the study participants. Most patients were able to increase peak force in the one-leg jump. In the two-leg jump, velocity and muscle power increased with equal or decreased muscle force. This may indicate an improvement in neuromuscular and intramuscular co-ordination (and therefore efficiency) with less muscle force necessary to generate the same power.
Roth
J
J
Children's Hospital of Eastern Ontario, Ottawa, Canada. jroth@cheo.on.ca
Wust
M
M
Rawer
R
R
Schnabel
D
D
Armbrecht
G
G
Beller
G
G
Rembitzki
I
I
Wahn
U
U
Felsenberg
D
D
Staab
D
D
D000328:Adult; D015519:Bone Density; D003550:Cystic Fibrosis / Q000503:physiopathology / Q000628:therapy*; D005541:Forced Expiratory Volume; D006801:Humans; D007866:Leg / Q000503:physiopathology; D008168:Lung / Q000503:physiopathology; D009068:Movement; D053580:Muscle Strength; D018482:Muscle, Skeletal / Q000503:physiopathology; D010865:Pilot Projects; D011884:Radius / Q000378:metabolism; D013131:Spine / Q000378:metabolism; D013977:Tibia / Q000378:metabolism; D013997:Time Factors; D016896:Treatment Outcome; D014732:Vibration / Q000627:therapeutic use*; D055815:Young Adult